Ketamine and its metabolites: Potential as novel treatments for depression

Neuropharmacology. 2023 Jun 1:230:109492. doi: 10.1016/j.neuropharm.2023.109492. Epub 2023 Mar 6.

Authors

Kenji Hashimoto¹, Shigeyuki Chaki²

Affiliations

¹ Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, 260-8670, Japan. Electronic address: hashimoto@faculty.chiba-u.jp.
² Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama, Saitama, 331-9530, Japan. Electronic address: s-chaki@taisho.co.jp.

PMID: 36889434
DOI: 10.1016/j.neuropharm.2023.109492

No abstract available

Publication types

Editorial

MeSH terms

Antidepressive Agents / pharmacology
Antidepressive Agents / therapeutic use
Bipolar Disorder* / drug therapy
Depression / drug therapy
Humans
Ketamine* / pharmacology
Ketamine* / therapeutic use

Substances

Ketamine
Antidepressive Agents